Systemic metabolic abnormalities: Key drivers of complications and mortality in MASLD

Metabolic dysfunction-associated steatotic liver disease (MASLD), as a new term that includes hepatic steatosis and cardiometabolic risk factors, has triggered numerous clinical discussions.1 This new definition highlights the interconnectedness between liver steatosis and various cardiometabolic risk factors.1 By shifting the focus to the broader spectrum of metabolic diseases, MASLD emphasizes the systemic nature of liver disease. Previous research has already demonstrated the impact of metabolic factors on the prevalence and severity of MASLD.